PSE Announcement

Due to the prodigious response to our press release regarding the Prostate Screening EpiSwitch® (PSE), we wanted to give everyone a quick update. Currently, the PSE is not commercially available, and no clinical trials are underway. We are working hard to bring this important test into the clinical lab for routine diagnostic testing. For more information regarding the PSE, please check out our press release and published article in Cancers. Thank you for being so supportive, and please check our website for future updates on this subject.

Continue

Featured Stories

Filter by:

New prostate cancer blood test combining PSA with epigenetic test could reduce biopsies

Cancerworld |
View Article

Scientists create ‘impressive’ new blood test for prostate cancer that is 94% accurate

The Independent |
View Article

New prostate cancer test could spare men from needless biopsies

The Telegraph |
View Article

New prostate cancer test is 94% accurate and could stop unnecessary biopsies, researchers say

ITV News |
View Article

Oxford BioDynamics’ Prostate Screening EpiSwitch® Blood Test Significantly Enhances Overall Detection Accuracy For At Risk Men

BioSpace |
View Article

Advancing cancer care with 3D genomics

Oxford BioDynamics Media Center |
View Article